Significance of Mucosal Healing Induced by Azathioprine for Patients with Ulcerative Colitis Yoshitaka Ueno 1 , Shinji Tanaka 1 , Rie Hanaoka 2 , Toshiko Onitake 2 , Kyoko Yoshioka 2 , Tsuyoshi Hatakeyama 2 , Masaru Shimamoto 2 , Shiro Oka 1 , Shigeto Yoshida 1 , Masaharu Yoshihara 3 , Kazuaki Chayama 2 1Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan 2Department of Medicine and Molecular Science, Hiroshima University, Hiroshima, Japan 3Health Service Center, Hiroshima University, Higashi-Hiroshima, Japan Keyword: 潰瘍性大腸炎 , 粘膜治癒 , アザチオプリン pp.1877-1884
Published Date 2007/12/25
DOI https://doi.org/10.11477/mf.1403101242
  • Abstract
  • Look Inside
  • Reference
  • Cited by

 Immunomodulators, such as azathioprine (AZA) have recently been re-evaluated for the treatment of ulcerative colitis (UC) in Japan. Infliximab has been reported to induce mucosal healing in Crohn's disease (CD), which may have a beneficial effect on the reduction of hospitalization and surgery. AZA had also been recognized as inductive of mucosal healing in CD. However, the significance of AZA on the induction of mucosal healing in UC remains unclear. Here, we analyzed 25 steroid-dependent UC cases treated with AZA and followed them up endoscopically between 2000 and 2007 at Hiroshima University Hospital.

 Our data indicates that AZA leads to mucosal healing which may induce clinical remission. Induction of mucosal healing in UC as well as in CD might be the ultimate endpoint of therapy with AZA.

Copyright © 2007, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院